How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment

Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S8-S11. doi: 10.1016/S2152-2650(20)30443-2.
No abstract available

Keywords: B-ALL; blinatumomab; children; inotuzumab ozogamicin; tisagenlecleucel.

MeSH terms

  • Adolescent
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Child
  • Humans
  • Immunotherapy / methods*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Risk Factors
  • Young Adult


  • Antineoplastic Agents, Immunological